Biomarkers and Prognostic Tools

/Biomarkers and Prognostic Tools

Reporting A Concerning Increase In The Number Of Men Diagnosed With Advanced Prostate Cancer

According to information from a published report from the Tuesday, July 19, 2016 edition of HealthDay News, there has been an explosion of new cases of advanced prostate cancer in the United States. They reported on a study using data on nearly 800,000 men listed in the National Cancer Data Base who had been diagnosed with prostate cancer between 2004 and 2013.   They concluded that new cases of advanced prostate cancer have skyrocketed by 72 percent in the past decade. They reported that the biggest increase was in the age group of men between 55 to 69 years. They point [...]

Understanding the Risk Factors for Hereditary Prostate Cancer – A Surprise

We often refer to prostate cancer as a family affair, or rather being passed on from father to son, etc. This is only partially true because there is still more prostate cancer diagnosed in men without any family history. For those cancers that are passed on from one family member to another it is important to understand the risks. This includes the risks for both being diagnosed and the risks for aggressiveness. It is generally accepted that if your brother has prostate cancer your risk of also having prostate cancer is doubled. But what does this really mean? Yes, you [...]

Standardizing PSA Definition of Biochemical Recurrence after Radical Prostatectomy

There are multiple definitions of biochemical recurrence for prostate cancer treatment post surgery. This causes confusion both within the patient community and the medical community. It would be very helpful if we could standardize a simple measure, PSA as the biomarker for a biochemical recurrence. Standardization post surgery would give us a better way to decide at what point additional treatment would most benefit a man with recurrent prostate cancer. To accomplish this goal researchers reviewed the long-term prostatectomy outcomes to assess the most appropriate prostate specific antigen cut point that predicts future disease progression. The study was large, including [...]

Better Predicting Advanced Prostate Cancer Outcomes with NaF-PET/CT Scans

Imaging of prostate cancer has been improving by leaps and bounds over the last few years. Current imaging techniques are not sensitive enough to give us an accurate picture of the cancer. This means that we lose predictive abilities and don’t always have adequate information to make the best treatment decisions. It also means, in some situations, that insurance will not always cover what is clearly the best treatment because we lack evidence of the actual disease state to qualify for the FDA label of certain treatments. In a move to develop better, more accurate scanning technology, a recent study [...]